• Explore /
  • Poster
  • / Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to assess the value of abiraterone acetate (AA) and enzalutamide (E) in advanced prostate cancer: clinical value and cost considerations.

Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to assess the value of abiraterone acetate (AA) and enzalutamide (E) in advanced prostate cancer: clinical value and cost considerations.

Abstract Poster

Authors

null

Sarah Wong

Princess Margaret Cancer Centre, Toronto, ON, Canada

Sarah Wong , Louis Everest , Di Maria Jiang , Ronak Saluja , Kelvin K. Chan , Srikala S. Sridhar

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr 276)

DOI

10.1200/JCO.2018.36.6_suppl.276

Abstract #

276

Poster Bd #

N8

Abstract Disclosures

Similar Posters

First Author: Michal Podrazil

Poster

2024 ASCO Genitourinary Cancers Symposium

Financial toxicity from PARP inhibitors in castrate-resistant prostate cancer.

Financial toxicity from PARP inhibitors in castrate-resistant prostate cancer.

First Author: David Joseph Benjamin

First Author: Christopher Sweeney

First Author: Alicia K. Morgans